Advances in Epigenetic Treatment of Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review Publisher Pubmed



Letafati A^{1, 2} ; Mehdigholian Chaijani R² ; Edalat F³ ; Eslami N⁴ ; Askari H⁵ ; Askari F⁶ ; Shirvani S⁷ ; Talebzadeh H⁷ ; Tarahomi M⁸ ; Mirkhani N⁹ ; Karimi F¹¹ ; Norouzi M^{1, 2} ; Mozhgani S¹⁰ Show Affiliations
Source: Clinical Epigenetics Published:2025

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) infection causes the uncommon and deadly cancer known as adult T-cell leukemia/lymphoma (ATLL), which affects mature T cells. Its clinical appearance is varied, and its prognosis is often miserable. Drug resistance to conventional therapies confers significant therapeutic challenges in the management of ATLL. This review discusses the emerging role of epigenetic medical advances in the treatment of ATLL, focusing on DNA methyltransferase inhibitors, histone deacetylase inhibitors, histone methyltransferase inhibitors, and BET inhibitors. Indeed, several classes of epigenetic therapies currently exhibit trailed efficacy in preclinical and clinical studies: DNA methyltransferase inhibitors like azacitidine and decitabine reexpression of silenced tumor suppressors; histone deacetylase inhibitors like vorinostat and romidepsin induce cell cycle arrest and apoptosis; bromodomain and extra-terminal inhibitors like JQ1 disrupt oncogenic signaling pathways. Whereas preclinical and early clinical data indicate modest to good efficacy for such treatments, significant challenges remain. Here, we discuss the current state of understanding of epigenetic dysregulation in ATLL and appraise the evidence supporting the use of these epi-drugs. However, despite the opened doors of epigenetic treatment, much more research is required with regard to showing the best combinations of drugs and their resistance mechanisms, the minimization of adverse effects, and how this hope will eventually be translated into benefit for the patient with ATLL. © The Author(s) 2025.